CEL-SCI is focused on its research and development initiatives directed at improving the treatment of cancer and other diseases by using the body’s natural defense system, the immune system. It is developing treatments for use against cancer, rheumatoid arthritis, and various viruses, including H1N1, H5N1, and the Avian Flu.

Its lead investigational drug is Multikine (Leukocyte Interleukin, Injection), which is currently being studied in a key global Phase III clinical trial. Multikine is the first immunotherapeutic agent being developed as a potential first-line treatment for advanced primary head and neck cancers. It would be the first-of-its-kind treatment, using the immune system, for cancer.

The Phase III study is enrolling patients with advanced primary and not yet treated head and neck cancer on three continents. The objective of the study is to demonstrate a significant minimum 10% improvement in overall survival of patients that are treated with Multikine plus ‘standard of care’ treatment versus ‘standard of care’ treatment by itself. Such treatment consists of surgery plus radiation/chemotherapy.

Patients will receive 15 local injections of Multikine over a three week period prior to standard treatment. The injections are administered in the area of the adjacent lymph nodes since that is where the tumor is likely to recur. Multikine is intended to create an anti-tumor response to reduce tumor recurrence and thus increase the survival rate of patients.

The company announced today that it released a new video about Multikine and the manufacturing to produce the drug, which is located near Baltimore, Maryland. The video and other information about CEL-SCI can be found at www.cel-sci.com.

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net